JP2023506787A - Ｐａｒｐ阻害薬と組み合わせたａｔｒ阻害薬の使用 - Google Patents

Ｐａｒｐ阻害薬と組み合わせたａｔｒ阻害薬の使用 Download PDF

Info

Publication number
JP2023506787A
JP2023506787A JP2022535631A JP2022535631A JP2023506787A JP 2023506787 A JP2023506787 A JP 2023506787A JP 2022535631 A JP2022535631 A JP 2022535631A JP 2022535631 A JP2022535631 A JP 2022535631A JP 2023506787 A JP2023506787 A JP 2023506787A
Authority
JP
Japan
Prior art keywords
optionally substituted
cancer
alkyl
carcinoma
atr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022535631A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023506787A5 (https=
Inventor
コーラー、マリア
ジマーマン、ミハル
ルールストン、アン
Original Assignee
リペア セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リペア セラピューティクス インコーポレイテッド filed Critical リペア セラピューティクス インコーポレイテッド
Publication of JP2023506787A publication Critical patent/JP2023506787A/ja
Publication of JP2023506787A5 publication Critical patent/JP2023506787A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022535631A 2019-12-11 2020-12-11 Ｐａｒｐ阻害薬と組み合わせたａｔｒ阻害薬の使用 Pending JP2023506787A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962946876P 2019-12-11 2019-12-11
US62/946,876 2019-12-11
PCT/US2020/064662 WO2021119523A1 (en) 2019-12-11 2020-12-11 Use of atr inhibitors in combination with parp inhibitors

Publications (2)

Publication Number Publication Date
JP2023506787A true JP2023506787A (ja) 2023-02-20
JP2023506787A5 JP2023506787A5 (https=) 2023-12-18

Family

ID=76316464

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022535631A Pending JP2023506787A (ja) 2019-12-11 2020-12-11 Ｐａｒｐ阻害薬と組み合わせたａｔｒ阻害薬の使用

Country Status (12)

Country Link
US (2) US20210177856A1 (https=)
EP (1) EP4072551A4 (https=)
JP (1) JP2023506787A (https=)
KR (1) KR20220128350A (https=)
CN (1) CN115103677A (https=)
AU (1) AU2020402108A1 (https=)
BR (1) BR112022011426A2 (https=)
CA (1) CA3164203A1 (https=)
CL (1) CL2022001540A1 (https=)
IL (1) IL293810A (https=)
MX (1) MX2022007163A (https=)
WO (1) WO2021119523A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019373416A1 (en) 2018-10-30 2021-06-10 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors
BR112023024942A2 (pt) * 2021-06-16 2024-02-15 Repare Therapeutics Inc Uso de inibidores de atr em combinação com inibidores de parp para tratamento de câncer
CN119212710A (zh) * 2022-04-07 2024-12-27 修复治疗公司 使用atr抑制剂的方法
US20250352539A1 (en) * 2022-06-15 2025-11-20 Astrazeneca Ab Combination therapy for treating cancer
WO2024164089A1 (en) * 2023-02-09 2024-08-15 Repare Therapeutics Inc. Use of atr inhibitors in the treatment of cancers with high tumor mutational burden
CN117159725B (zh) * 2023-04-06 2024-07-05 上海交通大学医学院附属仁济医院 通过dna水凝胶促进小分子药物结晶达到缓释效果的方法
WO2024243078A1 (en) * 2023-05-19 2024-11-28 Leapfrog Bio, Inc. Hsp90 inhibitors for the treatment of cancer
EP4716756A1 (en) * 2023-05-23 2026-04-01 The Francis Crick Institute Limited Targets for treatment of alt-positive cancers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018153973A1 (en) * 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combination of atr kinase inhibitors with parp inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2305221T3 (pl) * 2003-12-01 2015-11-30 Kudos Pharm Ltd Inhibitory naprawy uszkodzeń DNA w leczeniu raka
TWI656121B (zh) * 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
AU2019373416A1 (en) * 2018-10-30 2021-06-10 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors
KR20220035925A (ko) * 2019-07-22 2022-03-22 리페어 세라퓨틱스 인크. Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018153973A1 (en) * 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combination of atr kinase inhibitors with parp inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CLIN. CANCER RES., vol. 23, no. 12, JPN6024048852, 2017, pages 3097 - 3108, ISSN: 0005603415 *

Also Published As

Publication number Publication date
MX2022007163A (es) 2022-08-25
AU2020402108A1 (en) 2022-07-14
WO2021119523A8 (en) 2021-08-05
EP4072551A4 (en) 2023-11-15
BR112022011426A2 (pt) 2022-08-30
IL293810A (en) 2022-08-01
KR20220128350A (ko) 2022-09-20
US20240350505A1 (en) 2024-10-24
CA3164203A1 (en) 2021-06-17
CL2022001540A1 (es) 2023-01-13
EP4072551A1 (en) 2022-10-19
CN115103677A (zh) 2022-09-23
WO2021119523A1 (en) 2021-06-17
US20210177856A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
JP2023506787A (ja) Ｐａｒｐ阻害薬と組み合わせたａｔｒ阻害薬の使用
JP2024522736A (ja) がん治療のためのｐａｒｐ阻害剤と組み合わせたａｔｒ阻害剤の使用
US20130224151A1 (en) Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
CN104023715B (zh) 激酶抑制剂的副作用降低剂
JP2017014224A (ja) 帯状疱疹関連痛の急性期疼痛の予防又は治療剤
JP2025511732A (ja) Ａｔｒ阻害薬の使用方法
JPWO2006088193A1 (ja) 抗腫瘍剤
ES2749433T3 (es) Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática
CN107207510A (zh) 联合疗法
CN112204025B (zh) 用于治疗疼痛的化合物，包含其的组合物以及使用其的方法
CN113329749A (zh) 用于治疗葡萄膜黑色素瘤的联合疗法
CN110290788A (zh) 氨基甲酸酯化合物用于预防、缓解或治疗双相障碍的用途
EP4656193A1 (en) Pharmaceutical composition for treating tumors
HK40079144A (en) Use of atr inhibitors in combination with parp inhibitors
IL298864A (en) Alkenyl pyrimidine compound, preparation method therefor, and application thereof
HK40107484A (zh) Atr抑制剂与parp抑制剂的组合用於治疗癌症的用途
PT1757283E (pt) Potenciador do efeito antitumoral, agente antitumoral e método para a terapia do cancro
CN117500506A (zh) Atr抑制剂与parp抑制剂的组合用于治疗癌症的用途
WO2024164089A1 (en) Use of atr inhibitors in the treatment of cancers with high tumor mutational burden
JP2022526755A (ja) 化合物バフィデムスタット（ｖａｆｉｄｅｍｓｔａｔ）などｋｄｍ１ａ阻害剤を使用した注意欠陥多動性障害の処置方法
WO2025181153A1 (en) Use of atr inhibitors in combination with pi3k alpha inhibitors
KR102895850B1 (ko) Isa-2011b와 엘로티닙을 포함하는 암 예방 또는 치료를 위한 병용 투여용 약학적 조성물
MX2008001971A (es) Combinacion de compuestos organicos.
MX2008000900A (es) Combinacion que comprende pirimidil-amino-benzamidas y un inhibidor de flt-3 para el tratamiento de enfermedades proliferativas.
JP2007063205A (ja) 神経因性疼痛治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250527